Overview

The progression towards a pan-European HTA framework will pose new challenges to device and diagnostics companies as they contend with a heightened focus on higher quality evidence, with unchanged local decisionmaking around reimbursement.  This session will explore concepts in evidence development for medical technologies, and how European payment systems have evolved to demand greater clinical and economic value than ever before.